A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Venetoclax (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 10 Jun 2017 Biomarkers information updated
- 13 Feb 2017 Planned End Date changed from 1 Jul 2020 to 1 Jun 2020.
- 12 Dec 2016 Planned End Date changed from 1 Dec 2019 to 1 Jul 2020.